KR20160001102A - Hair cosmetic composition comprising the oriental medicin extract of Graviola for improving state of scalp and preventing hair loss - Google Patents
Hair cosmetic composition comprising the oriental medicin extract of Graviola for improving state of scalp and preventing hair loss Download PDFInfo
- Publication number
- KR20160001102A KR20160001102A KR1020140078896A KR20140078896A KR20160001102A KR 20160001102 A KR20160001102 A KR 20160001102A KR 1020140078896 A KR1020140078896 A KR 1020140078896A KR 20140078896 A KR20140078896 A KR 20140078896A KR 20160001102 A KR20160001102 A KR 20160001102A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- extract
- parts
- graviola
- hair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 210000004209 hair Anatomy 0.000 title claims abstract description 21
- 210000004761 scalp Anatomy 0.000 title claims abstract description 19
- 239000002537 cosmetic Substances 0.000 title claims abstract description 17
- 230000003658 preventing hair loss Effects 0.000 title claims abstract description 11
- 239000000284 extract Substances 0.000 title claims description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 239000000469 ethanolic extract Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- 235000002789 Panax ginseng Nutrition 0.000 claims description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 7
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 7
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 7
- 229940008099 dimethicone Drugs 0.000 claims description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 7
- 239000003205 fragrance Substances 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 229960005150 glycerol Drugs 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 claims description 6
- 244000299790 Rheum rhabarbarum Species 0.000 claims description 6
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 229940100608 glycol distearate Drugs 0.000 claims description 6
- 229940109529 pomegranate extract Drugs 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 240000002045 Guettarda speciosa Species 0.000 claims description 5
- 102000011782 Keratins Human genes 0.000 claims description 5
- 108010076876 Keratins Proteins 0.000 claims description 5
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 5
- 235000011613 Pinus brutia Nutrition 0.000 claims description 5
- 241000018646 Pinus brutia Species 0.000 claims description 5
- 235000020710 ginseng extract Nutrition 0.000 claims description 5
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 claims description 4
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 claims description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims description 2
- OHIXTOQGHGVGEK-UHFFFAOYSA-N C(CCC)NC(OC(CCI)=O)=O Chemical compound C(CCC)NC(OC(CCI)=O)=O OHIXTOQGHGVGEK-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229940046554 solanum tuberosum extract Drugs 0.000 claims description 2
- YZTJKOLMWJNVFH-UHFFFAOYSA-N 2-sulfobenzene-1,3-dicarboxylic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1S(O)(=O)=O YZTJKOLMWJNVFH-UHFFFAOYSA-N 0.000 claims 1
- 125000005442 diisocyanate group Chemical group 0.000 claims 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 201000004384 Alopecia Diseases 0.000 abstract description 15
- 230000003676 hair loss Effects 0.000 abstract description 14
- 208000024963 hair loss Diseases 0.000 abstract description 14
- 230000003779 hair growth Effects 0.000 abstract description 5
- 230000000845 anti-microbial effect Effects 0.000 abstract description 4
- 239000012676 herbal extract Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000037307 sensitive skin Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 239000012488 sample solution Substances 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000186427 Cutibacterium acnes Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- -1 ABTS cation Chemical class 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000037333 procollagen synthesis Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 2
- 101710140438 Cathelicidin antimicrobial peptide Proteins 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 240000005125 Myrtus communis Species 0.000 description 2
- 235000013418 Myrtus communis Nutrition 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- LVQSCKUKDKAQGO-UHFFFAOYSA-L disodium;diiodide Chemical compound [Na+].[Na+].[I-].[I-] LVQSCKUKDKAQGO-UHFFFAOYSA-L 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 230000002849 elastaseinhibitory effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 229940057950 sodium laureth sulfate Drugs 0.000 description 2
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- URLVCROWVOSNPT-XOTOMLERSA-N (2s)-4-[(13r)-13-hydroxy-13-[(2r,5r)-5-[(2r,5r)-5-[(1r)-1-hydroxyundecyl]oxolan-2-yl]oxolan-2-yl]tridecyl]-2-methyl-2h-furan-5-one Chemical compound O1[C@@H]([C@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCCCCC=2C(O[C@@H](C)C=2)=O)CC1 URLVCROWVOSNPT-XOTOMLERSA-N 0.000 description 1
- WCBPJVKVIMMEQC-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 WCBPJVKVIMMEQC-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- CPOBTYJRKAJERX-UHFFFAOYSA-N 3-ethyl-n-[(3-ethyl-1,3-benzothiazol-2-ylidene)amino]-1,3-benzothiazol-2-imine Chemical compound S1C2=CC=CC=C2N(CC)C1=NN=C1SC2=CC=CC=C2N1CC CPOBTYJRKAJERX-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 1
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000233614 Phytophthora Species 0.000 description 1
- KMNTUASVUKNVJS-UHFFFAOYSA-N Ponceau S (acid form) Chemical compound OC1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C=CC2=C1N=NC(C(=C1)S(O)(=O)=O)=CC=C1N=NC1=CC=C(S(O)(=O)=O)C=C1 KMNTUASVUKNVJS-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000245165 Rhododendron ponticum Species 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- QUHYUSAHBDACNG-UHFFFAOYSA-N acerogenin 3 Natural products C1=CC(O)=CC=C1CCCCC(=O)CCC1=CC=C(O)C=C1 QUHYUSAHBDACNG-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- URLVCROWVOSNPT-QTTMQESMSA-N desacetyluvaricin Natural products O=C1C(CCCCCCCCCCCC[C@@H](O)[C@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 URLVCROWVOSNPT-QTTMQESMSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- KEAYESYHFKHZAL-IGMARMGPSA-N sodium-23 atom Chemical compound [23Na] KEAYESYHFKHZAL-IGMARMGPSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 그라비올라 한방 추출물을 포함하는 모발 화장료 조성물에 관한 것이다. 보다 상세하게는, 본 발명은 두피 개선 및 탈모 방지 효과를 갖춘 그라비올라 한방 추출물을 포함하는 모발 화장료 조성물에 관한 것이다.
본 발명에 따른 탈모 방지 및 두피 개선용 모발 화장료 조성물은 인체 친화적 천연 화장품으로서, 항균력이 있는 그라비올라 수를 포함하고 있어서 인체 피부에 무해하고 민감성 피부를 가진 사람에게도 쉽게 사용할 수 있다. 또한, 모발 성장 촉진에 효과적으로 작용하고, 두피 모근을 자극해 탈모예방에도 도움을 줄 뿐만 아니라 모발을 효과적으로 생장시킬 수 있는 장점이 있다. The present invention relates to a hair cosmetic composition comprising a graviolan herbal extract. More particularly, the present invention relates to a hair cosmetic composition comprising a graviolan herbal extract having scalp improvement and hair loss prevention effect.
The hair cosmetic composition for preventing hair loss and scalp according to the present invention is a human-friendly natural cosmetic composition containing graviola water having antimicrobial activity, so that it can be easily used for a person having harmless and sensitive skin to human skin. In addition, it acts effectively to promote hair growth, stimulates scalp hair roots to help prevent hair loss, and also has the advantage of effectively growing hair.
Description
본 발명은 그라비올라 한방 추출물을 포함하는 모발 화장료 조성물에 관한 것이다. 보다 상세하게는, 본 발명은 두피 개선 및 탈모 방지 효과를 갖는 그라비올라 한방 추출물을 포함하는 모발 화장료 조성물에 관한 것이다.
The present invention relates to a hair cosmetic composition comprising a graviolan herbal extract. More particularly, the present invention relates to a hair cosmetic composition comprising a graviolan herbal extract having an effect of improving scalp and preventing hair loss.
머리카락은 하루에 80~100개 정도가 정상적으로 빠지며 빠진 자리에는 새로운 모발이 형성되게 된다. 탈모는 머리카락이 새로 형성되는 숫자보다 빠지는 숫자가 더 많은 상태를 말하는 것으로, 탈모의 원인은 개인에 따라 다르지만, 유전적인 요인, 두피 및 건강 관리 상태 및 스트레스 등을 주요 원인으로 들 수 있다. 혈액순환이 잘 되면 모근에 영양분과 산소가 원활하게 공급되어 모발이 건강하게 자라지만, 고지방식이나 흡연 등으로 혈액순환이 원활하지 않으면 탈모가 촉진된다. 현대 사회에서는 탈모를 고민하는 사람들의 수가 점점 늘어나고 있으며 그 연령층이 점점 낮아지는 실정이다. The hair normally falls off about 80 ~ 100 per day and new hair is formed in the missing spot. The cause of hair loss varies from person to person, but genetic factors, scalp and health condition and stress are the main causes of hair loss. When blood circulation is good, nutrients and oxygen are supplied smoothly to the hair follicles and hair grows healthy. However, if blood circulation is not smooth due to high fat diet or smoking, hair loss is promoted. In modern society, the number of people who are worried about hair loss is increasing and the age group is getting lower.
탈모증을 치료하기 위한 종래의 발모 촉진용 약물 중 현재까지 미국 식품의약국(FDA)으로부터 탈모치료제로서 효능을 승인받은 제품으로는 경구용 피나스테라이드(Finasteride, Merk, 미국)와 외용제 미녹시딜(Minoxidil, Upjohn, 미국)의 두 가지가 알려져 있다. 미녹시딜은 모세혈관 확장 기능이 있어 두피에 바름으로써 탈모 방지 효과를 나타내지만, 지속적으로 두피에 발라야 하며, 일정 시간 약제가 두피에 머무르도록 해야만 효과가 나타나고, 가려움증이나 자극 등의 부작용이 나타나고 있다. 피나스테라이드는 탈모를 유발하는 남성호르몬인 DHT(5α-dihydrotestosterone) 생성 억제 기능이 있고, 장기 복용시 탈모 억제 효과가 나타나지만, 복용을 중단하면 원상태로 되돌아가는 문제점이 있다. 또한, 부작용으로서 성욕감퇴 및 발기부전 등의 성기능 감퇴 등이 있으며, 여성은 기형아 출산의 위험이 있어서 복용해서는 안 되는 것으로 알려져 있다. 즉, 종래 사용되던 탈모 방지제는 화학물질을 사용한 것으로서, 일시적인 혈류 유통에 의해 모세혈관을 확장하여 모근에 자극을 주는 것이므로 그 효과가 일시적일 뿐만 아니라 과다 분비된 피지에 의한 탈모에만 효과가 한정된다는 문제점도 있다. Among the conventional hair growth stimulating drugs for treating alopecia, there have been approved drugs for treating hair loss from the US Food and Drug Administration (FDA) such as oral finasteride (MERK, USA) and minoxidil, Upjohn, USA) are known. Minoxidil has a capillary vasodilating function, which is effective against hair loss by applying to the scalp. However, it has to be applied continuously to the scalp. When the medicine is kept on the scalp for a certain period of time, the effect appears and side effects such as itching and irritation are appearing. Pinasteride has the ability to inhibit the production of DHT (5α-dihydrotestosterone), a male hormone that causes hair loss, and has a hair restraining effect when taken over a long period of time. In addition, side effects such as loss of sexual desire and erectile dysfunction, such as erectile dysfunction, and women are at risk of birth defects and should not be taken. That is, since the conventional hair-loss preventive agent is made of a chemical substance, it temporarily expands the capillary blood vessels by circulating blood flow and stimulates the hair follicle, so that the effect is not only temporary but also limited in the effect of hair loss by excessive secretion of sebum There is also.
최근 연구 보고에 의하면 화학적으로 유도된 산화적 스트레스를 두피에 가할 경우, 모발의 주기가 유의적으로 단축되고, 피지의 산화에서 유발되는 탈모가 발생한다고 알려져 있다. 또한, 다양한 항산화 물질들이 탈모의 예방 및 발모 촉진에 효과가 있음이 알려지고 있다. Recent research reports indicate that when chemically induced oxidative stress is applied to the scalp, hair cycle is significantly shortened and hair loss induced by oxidation of sebum occurs. It is also known that various antioxidants are effective in preventing hair loss and promoting hair growth.
생약 성분의 추출물을 이용하여 두피에 바르거나 복용하여 탈모를 방지하고 발모를 촉진하려는 시도 또한 많이 알려져 있다. 대한민국 등록특허공보 제 10-780180호 (숙지황, 산수유, 택사, 산약, 복령 및 목단피를 이용하는 경우), 대한민국 등록특허공보 제 10-1103651호(측백엽, 고삼, 단삼, 박하, 한련초, 후박의 6가지 한방 생약제제의 추출물을 이용하는 경우) 및 대한민국 등록특허공보 제 10-1155502호(상백피, 감초, 의이인, 갈조, 인삼, 고삼 및 은행잎의 추출물을 이용하는 경우) 등 상기의 문제점을 해결하기 위한 많은 연구가 진행되고 있으나, 탈모를 방지하고 두피를 개선하기 위한 다양한 치료제들이 제시되었으나 현재까지 상기의 문제점을 근본적으로 해결하는데 있어서는 적절하지 못한 상태이다.Attempts to prevent hair loss and to promote hair growth have been known to be applied to the scalp using an extract of the herbal medicine component. Korean Patent Publication No. 10-780180 (when using Sukjihuang, Sansui, Pharmacopoeia, Acanthopanax senticosus, Bacillus subtilis and Mulberry), Korean Patent Registration No. 10-1103651 (6 kinds of papaya, Many studies have been conducted to solve the above problems, such as the case of using an extract of oriental herbal medicine) and Korean Patent Registration No. 10-1155502 (when using extracts of phytophthora, licorice, nifty ginseng, ginseng, However, various therapeutic agents for preventing hair loss and improving the scalp have been proposed, but it is not appropriate to fundamentally solve the above problems.
이에 본 발명자들은 상기 종래기술의 한계를 극복하는 신규한 탈모 방지 조성물을 개발하고자 노력한 결과, 항산화물질인 파이토케미칼(phytochemicals) 성분 및 아세토제닌(acetogenin) 성분을 함유하는 그라비올라 추출물의 항균 활성, 피부세포의 증식 향상 효과를 확인하고 그라비올라 추출물, 한약 소재 추출물 및 코퍼펩타이드를 복합 처방한 헤어 샴푸의 우수한 탈모 방지 및 두피 개선 효과를 확인함으로써, 본 발명을 완성하였다.
Accordingly, the present inventors have made efforts to develop a novel anti-hair-restoring composition that overcomes the limitations of the prior art, and as a result, they have found that the antimicrobial activity of graviola extract containing an antioxidant phytochemicals component and acetogenin component, Confirming the effect of enhancing cell proliferation and confirming the effect of preventing hair loss and improving the scalp of hair shampoos containing graviola extract, extract of herbal medicine material and copper peptides, and completed the present invention.
이와 같이, 본 발명은 그라비올라 추출물을 기반으로 하고 한방 추출물 및 카퍼트리펩타이드를 추가로 포함하는 탈모 방지 및 두피 개선용 모발 화장료 조성물 및 이의 제조방법을 제공하는 것을 목적으로 한다.
Thus, it is an object of the present invention to provide a hair cosmetic composition for hair loss prevention and scalp improvement, which further comprises a herbal extract and a capper tripeptide based on graviola extract, and a process for producing the same.
상기 본 발명의 목적을 달성하기 위해, 본 발명은 일 구체예에서, 다음의 단계를 포함하는 탈모 방지 및 두피 개선용 화장료 조성물의 제조방법: 1) 정제수, 카보머 및 디소듐이디티에이를 90℃까지 가온하여 용해한 후 여과하는 단계; 2) 시크릭애씨드, 솔잣나무열매추출물, 글리세린, 디메치콘, 소듐라우릴설페이트 및 코카마이도프로필베타인을 70℃까지 가온하여 용해한 후 상기 1) 단계의 여과물과 혼합교반하는 단계; 3) 코카마이드디이에이, 아이오도프로피닐부틸카바메이트 및 글라이콜디스테아레이트를 70℃까지 가온하여 용해한 후 여과하여 상기 2) 단계의 생성물과 혼합교반하여 60℃까지 냉각하는 단계; 4) 세트리모늄클로라이드, 향료, 트리에탄올아민, 소듐클로라이드, 하이드롤라이즈케라틴, 하수오추출물, 홍삼추출물, 백지추출물, 한련초추출물, 당귀추출물, 석류추출물, 대황추출물, 카퍼트리펩타이드, 그라비올라 에탄올 추출물, 소듐라우레스에테르설페이트 및 그라비올라 열수 추출물을 상기 3) 단계의 생성물과 혼합 교반하여 60℃까지 냉각하고 여과하는 단계:을 제공한다. 상기 구체예에서, 정제수 13 내지 17 중량부, 카보너 0.1 내지 0.3 중량부, 디소듐이디티에이 0.05 내지 0.1 중량부, 시크릭애씨드 0.1 내지 0.3 중량부, 솔잣나무열매추출물 0.1 내지 0.3 중량부, 글리세린 1.5 내지 2.0 중량부, 디메치콘 1.5 내지 2.5 중량부, 소듐라우릴설페이트 8 내지 12 중량부, 코카마이도프로필베타인 6 내지 8 중량부, 코카마이드디이에이 6 내지 8 중량부, 아이오도프로피닐부틸카바메이트 0.03 내지 0.05 중량부, 글라이콜디스테아레이트 0.3 내지 0.5 중량부, 세트리모늄클로라이드 1.8 내지 2.2 중량부, 향료 0.3 내지 0.7 중량부, 트리에탄올아민 0.3 내지 0.7 중량부, 소듐클로라이드 0.3 내지 0.7 중량부, 하이드롤라이즈드케라틴 0.8 내지 1.2 중량부, 하수오추출물 0.13 내지 0.15 중량부, 홍삼추출물 0.13 내지 0.15 중량부, 백지추출물 0.13 내지 0.15 중량부, 한련초추출물 0.13 내지 0.15 중량부, 당귀추출물 0.13 내지 0.15 중량부, 석류추출물 0.13 내지 0.15 중량부, 대황추출물 0.13 내지 0.15 중량부, 카퍼트리펩타이드 0.15 내지 0.25 중량부, 그라비올라 에탄올 추출물 0.4 내지 0.6 중량부, 소듐라우에스에테르설페이트 23 내지 27 중량부 및 그라비올라 열수추출물 23 내지 27중량부로 혼합하는 것을 특징으로 하는 방법을 제공하는데, 보다 상세하게는, 정제수 15 중량부, 카보너 0.2 중량부, 디소듐이디티에이 0.07 중량부, 시크릭애씨드 0.2 중량부, 솔잣나무열매추출물 0.2 중량부, 글리세린 1.7 중량부, 디메치콘 2 중량부, 소듐라우릴설페이트 10 중량부, 코카마이도프로필베타인 7 중량부, 코카마이드디이에이 7 중량부, 아이오도프로피닐부틸카바메이트 0.04 중량부, 글라이콜디스테아레이트 0.4 중량부, 세트리모늄클로라이드 2 중량부, 향료 0.5 중량부, 트리에탄올아민 0.5 중량부, 소듐클로라이드 0.5 중량부, 하이드롤라이즈드케라틴 1 중량부, 하수오추출물 0.143 중량부, 홍삼추출물 0.143 중량부, 백지추출물 0.143 중량부, 한련초추출물 0.143 중량부, 당귀추출물 0.143 중량부, 석류추출물 0.143 중량부, 대황추출물 0.143 중량부, 카퍼트리펩타이드 0.2 중량부, 그라비올라 에탄올추출물 0.5 중량부, 소듐라우에스에테르설페이트 25 중량부 및 그라비올라 열수추출물 25 중량부로 혼합하는 것을 특징으로 하는 방법을 제공한다.In order to accomplish the object of the present invention, in one embodiment, the present invention provides a method for preparing a cosmetic composition for preventing hair loss and scalp comprising the steps of: 1) dissolving purified water, carbomer, and disodium di ≪ / RTI > and then filtered; 2) dissolving Saccharic acid, Solanum tuberosum extract, glycerin, dimethicone, sodium lauryl sulfate and cocamidopropyl betaine to 70 ° C and mixing and mixing with the filtrate of step 1); 3) dissolving cocamide diame, iodopropionyl butylcarbamate and glycol distearate by heating to 70 ° C, filtering and mixing the product with the product of step 2), and cooling to 60 ° C; 4) Rumonium chloride, fragrance, triethanolamine, sodium chloride, hydrolyzed keratin, dewatering extract, red ginseng extract, white ginseng extract, hanchikcho extract, angelica extract, pomegranate extract, rhubarb extract, capper tripeptide, graviola ethanol extract, Mixing the sodium laureth ether sulfate and the graviola hot water extract with the product of step 3), cooling to 60 ° C and filtering. In the above-mentioned specific example, 13 to 17 parts by weight of purified water, 0.1 to 0.3 parts by weight of carbonon, 0.05 to 0.1 part by weight of disodium iodide, 0.1 to 0.3 parts by weight of cicric acid, 0.1 to 0.3 part by weight of sour pine fruit extract, 1.5 to 2.0 parts by weight of glycerin, 1.5 to 2.5 parts by weight of dimethicone, 8 to 12 parts by weight of sodium lauryl sulfate, 6 to 8 parts by weight of cocamidopropyl betaine, 6 to 8 parts by weight of cocamide dielite, 0.03 to 0.05 part by weight of neo-butylcarbamate, 0.3 to 0.5 part by weight of glycol distearate, 1.8 to 2.2 parts by weight of settimorium chloride, 0.3 to 0.7 part by weight of fragrance, 0.3 to 0.7 part by weight of triethanolamine, , 0.13 to 0.15 parts by weight of red ginseng extract, 0.13 to 0.15 parts by weight of white ginseng extract, 0.13 to 0.15 parts by weight of the extract, 0.13 to 0.15 parts by weight of Angelica gigantosa extract, 0.13 to 0.15 part by weight of the pomegranate extract, 0.13 to 0.15 part by weight of the rhubarb extract, 0.15 to 0.25 part by weight of the caprate tripeptide, 0.4 to 0.6 part by weight of the graviola ethanol extract 23 to 27 parts by weight of sodium laureth sulfate and 23 to 27 parts by weight of a graviola hot water extract. More specifically, 15 parts by weight of purified water, 0.2 part by weight of carborane, 0.2 part by weight of cyclic acid, 0.2 part by weight of sour pine nut extract, 1.7 parts by weight of glycerin, 2 parts by weight of dimethicone, 10 parts by weight of sodium lauryl sulfate, 7 parts by weight of cocamidopropyl betaine 7 parts by weight of cocamide dieye, 0.04 part by weight of iodopropynyl butylcarbamate, 0.4 part by weight of glycol distearate, 0.5 part by weight of fragrance, 0.5 part by weight of triethanolamine, 0.5 part by weight of sodium chloride, 1 part by weight of hydrolyzed keratin, 0.143 part by weight of Sasao extract, 0.143 part by weight of red ginseng extract, 0.143 part by weight of Bleach extract, 0.143 weight part of Angelica giganta extract, 0.143 weight part of pomegranate extract, 0.143 weight part of rhubarb extract, 0.2 weight part of kappa tripeptide, 0.5 weight part of graviola ethanol extract, 25 weight part of sodium laureth sulfate and 25 weight of graviola hot water extract Lt; / RTI > by weight.
본 발명의 다른 일 구체예에서는 상기 구체예에서 제조된 생성물을 유효성분으로 포함하는 탈모 방지 및 두피 개선용 모발 화장료 조성물을 제공한다.
Another embodiment of the present invention provides a hair cosmetic composition for preventing hair loss and improving scalp comprising the product prepared in the above embodiment as an active ingredient.
본 발명에 따른 탈모 방지 및 두피 개선용 모발 화장료 조성물은 인체 친화적 천연 화장품으로서, 세포독성이 낮고 항균력이 있는 그라비올라 추출물을 포함하고 있어서 인체 피부에 무해하고 민감성 피부를 가진 사람에게도 쉽게 사용할 수 있다. 또한, 모발 성장 촉진에 효과적으로 작용하고, 두피 모근을 자극해 탈모예방에도 도움을 줄 뿐만 아니라 모발을 효과적으로 생장시킬 수 있는 장점이 있다.
The hair cosmetic composition for prevention of hair loss and scalp according to the present invention is a human-friendly natural cosmetic product, which contains graviola extract having low cytotoxicity and antibacterial activity, and thus can be easily used for a person having harmless and sensitive skin to human skin. In addition, it acts effectively to promote hair growth, stimulates scalp hair roots to help prevent hair loss, and also has the advantage of effectively growing hair.
도 1 내지 도 4는 그라비올라 추출물의 항산화 효과를 측정한 결과를 나타낸 것이다.
도 5는 그라비올라 추출물의 세포 독성을 측정한 결과를 나타낸 것이다.
도 6은 그라비올라 추출물의 티로시나아제 저해능을 측정한 결과를 나타낸 것이다.
도 7은 그라비올라 추출물의 프로콜라겐 합성에 대한 효과를 나타낸 것이다.
도 8은 그라비올라 추출물의 항균력을 측정한 결과를 나타낸 것이다.
도 9는 그라비올라 추출물의 항균 펩타이드 합성에 대한 효과를 나타낸 것이다.
도 10은 그라비올라 추출물의 주름개선효과를 엘라스타제 저해능에 의해 측정한 결과를 나타낸 것이다.
도 11 및 도 12는 그라비올라 추출물의 항염증 효과를 측정한 결과를 나타낸 것이다. 1 to 4 show the results of measuring antioxidative effects of graviola extract.
FIG. 5 shows the results of measurement of cytotoxicity of graviola extract.
Fig. 6 shows the results of measuring the inhibitory effect of tyrosinase on the graviola extract.
Figure 7 shows the effect of graviola extract on procollagen synthesis.
Fig. 8 shows the results of measuring the antibacterial activity of graviola extract.
Figure 9 shows the effect of graviola extract on the synthesis of antimicrobial peptides.
Fig. 10 shows the results of measurement of the wrinkle-improving effect of gravurea extract by an elastase inhibitor.
Figs. 11 and 12 show the results of measuring anti-inflammatory effects of graviola extract.
이하, 본 발명의 구성요소와 기술적 특징을 다음의 실시예들을 통하여 보다 상세하게 설명하고자 한다. 그러나 하기 실시예들은 본 발명의 내용을 예시하는 것일 뿐 발명의 범위가 실시예에 의해 한정되는 것은 아니다.Hereinafter, the components and technical features of the present invention will be described in more detail with reference to the following examples. However, the following examples are intended to illustrate the contents of the present invention and are not intended to limit the scope of the invention.
실시예Example
추출물의 제조Preparation of extract
1.1 그라비올라 에탄올 추출물1.1 Graviola Ethanol Extract
그라비올라잎 및 에탄올(70%)을 1:100 중량비로 혼합하여 24H 롤링 추출기에서 추출물을 제조하였다. 제조된 추출물은 건조시켜 파우더로 만들었다.
Graviola leaves and ethanol (70%) were mixed at a weight ratio of 1: 100 to prepare an extract from a 24H rolling extractor. The prepared extract was dried to make powder.
1.2 그라비올라 열수 추출물1.2 Graviola hot water extract
그라비올라잎 및 화장품 정제수를 1:200 중량비로 100℃까지 열탕하여 추출물을 제조하였다.
Graviola leaves and cosmetics purified water were heated to 100 ° C at a weight ratio of 1: 200 to prepare an extract.
1.3 단오수 추출물1.3 Single water extract
대황, 한련초, 하수오, 백지 석류, 인삼, 당귀를 부틸렌글리콜과 글리세린 혼합하여 수용액으로 제조한 후 70℃ 내지 80℃에서 중탕하였다. 1㎛ 필터로 여과를 실시한 후 방냉하여 상온에 방치하였다. 0.8 ㎛ 및 0.45 ㎛ 필터로 2차 여과를 실시한 후 방부제를 처리한 후 0.2 ㎛ 필터로 3차 여과를 실시하였다.
Ginseng, and ginseng were mixed with butylene glycol and glycerin to prepare an aqueous solution, and the mixture was stirred at 70 ° C to 80 ° C. The mixture was filtered with a 1 mu m filter, allowed to cool, and left at room temperature. After secondary filtration with 0.8 ㎛ and 0.45 ㎛ filters, the preservative was treated and then subjected to tertiary filtration with 0.2 ㎛ filter.
효능 테스트Efficacy test
2.1 항산화 효과2.1 Antioxidant effect
1) DPPH 라디칼 소거능1) DPPH radical scavenging ability
DPPH 전자공여능은 Blois의 방법(비특허문헌 1)에 따라 측정하였다. 그라비올라 추출물을 포함하는 각 시료용액 2 mL에 0.2 mM 의 1,1-디페닐-2-피크릴히드라질(DPPH) 1 mL를 넣고 교반하였다. 30분간 방치한 후 517 nm에서 흡광도를 측정하였다. 전자공여능은 시료용액의 첨가구와 무첨가군의 흡광도 감소율로 나타내었다. 그라비올라 열수추출물 및 에탄올추출물에 대한 DPPH 라디칼 소거능 측정결과, 그라비올라 에탄올추출물 1,000 ug/ml에서 양성대조군 비타민-C(Vit-C)보다 우수한 효능효과를 확인하였다(도 1, 열수추출물 79%, 에탄올추출물 91%, 비타민 C 83%).
DPPH electron donating ability was measured according to the method of Blois (Non-Patent Document 1). To 2 mL of each sample solution containing graviola extract, 1 mL of 0.2
2) ABTS 양이온 라디칼 소거능 2) ABTS cation radical scavenging ability
ABTS (2,2'-azino-bis(3-ethylbenzthiazoline)-6-sulphonic acid) 양이온 라디칼을 이용한 항산화력 측정은 ABTS 양이온 탈색 시험(비특허 문헌 2)에 의하여 측정하였다. 7mM 2,2-아지노-비스(3-에틸벤즈티아졸린)-6-술폰산(ABTS)와 2.4mM 과황산칼륨(Potassium persulfate)를 최종 농도로 혼합하여 실온인 암소에서 24시간 동안 방치하여 ABTS+를 형성시킨 후 인산염 완충 식염수(PBS)로 희석하여 ABTS+ 100 uL를 가하여 1분 동안 방치한 후 732 nm에서 흡광도를 측정하였다. 그라비올라 열수추출물 및 그라비올라 에탄올추출물의 ABTS+ 라디칼 소거능 측정결과, 그라비올라 에탄올추출물 500 ㎍/㎖에서 양성대조군 비타민-C보다 우수한 효능효과를 확인하였다(도 2).
The antioxidant activity of ABTS (2,2'-azino-bis (3-ethylbenzthiazoline) -6-sulphonic acid) cation radical was measured by ABTS cation decolorization test (Non-Patent Document 2). (ABTS) and 2.4 mM potassium persulfate were mixed at a final concentration, and the mixture was allowed to stand in a dark place at room temperature for 24 hours to obtain ABTS + , And diluted with phosphate buffered saline (PBS). After incubation with
3) 슈퍼옥사이드 음이온 라디칼(superoxide anion radical) 소거능 3) superoxide anion radical scavenging ability
슈퍼옥사이드 음이온 라디칼 소거능은 NBT(nitrobule tetrazolium) 환원방법에 의해 측정하였다(비특허문헌 3). 각 시료용액 0.1 mL와 0.1M 칼륨 포스페이트 완충액(pH 7.5) 0.4 mL에 잔틴(Xanthine) 0.4 mM 과 NBT(0,24 mM)을 녹인 기질액 1 mL을 첨가하고 잔틴 산화효소(0,2 U/ML) 1ML를 가하여 37℃에서 20분간 반응시킨 후 1 N 염산 1 mL을 가하여 반응을 종료시켰다. 반응액 중에 생성된 슈퍼옥사이드 음이온 라디칼의 양은 560 nm에서의 흡광도에 의해 측정하였다. 그라비올라 열수추출물 및 그라비올라 에탄올추출물의 superoxide anion radical 소거능 측정결과, 그라비올라 열수추출물 1,000 ㎍/㎖에서 양성대조군 Vit-C 보다 우수한 효능효과를 확인하였다(도 3).
The superoxide anion radical scavenging activity was measured by NBT (nitrobule tetrazolium) reduction method (Non-Patent Document 3). Add 0.1 mL of each sample solution and 0.4 mL of 0.1 M potassium phosphate buffer solution (pH 7.5) and add 1 mL of a substrate solution containing 0.4 mM of Xanthine and 0.22 mM of NBT. ML) was added to the reaction mixture at 37 ° C for 20 minutes, followed by the addition of 1 mL of 1 N hydrochloric acid to terminate the reaction. The amount of superoxide anion radical produced in the reaction solution was measured by absorbance at 560 nm. As a result of the superoxide anion radical scavenging ability of the graviola hot water extract and graviola ethanol extract, 1,000 ㎍ / ㎖ of graviola hydrothermal extract showed better efficacy than the positive control Vit-C (FIG. 3).
4) 슈퍼옥사이드 디스뮤타제(SOD) 유사 활성능4) superoxide dismutase (SOD) similar bow performance
SOD 유사활성은 Marklund의 방법(비특허문헌 4)에 따라 측정하였다. 각 시료용액 0.2ML에 Tris-HCl의 완충용액 (50 mM Tris+10 mM EDTA, pH 8.5) 2.6ML와 7.2 MM 피로갈롤(pyrogallol)의 양을 420 nm에서 측정하였다. SOD 유사활성은 시료용액의 실험구와 대조구의 흡광도 감소율로 나타내었다. 그라비올라 열수추출물 및 그라비올라 에탄올추출물 1,000ug/ml에서 각 10.27%, 22.2%의 효능효과를 확인하였다(도 4). 활성산소와 인체내 독성을 제거하는 항산화효소의 활성도를 측정한 것으로 항산화력은 우수하게 측정되었으나 SOD(항산화효소)의 활성도는 비타민 C에 비하여 현저히 낮게 나타났다.
The SOD-like activity was measured according to the method of Marklund (Non-Patent Document 4). The amount of Tris-HCl buffer solution (50 mM Tris + 10 mM EDTA, pH 8.5) of 2.6 ML and 7.2 mM of pyrogallol was measured at 420 nm in 0.2 mL of each sample solution. SOD - like activity was expressed by the absorbance reduction rate of the experimental solution and the control solution of the sample solution. The efficacies of 10.27% and 22.2% of the extracts of graviola hydrothermal extract and graviola ethanol were observed at 1,000 ug / ml (FIG. 4). The activity of antioxidant enzymes that remove free radicals and toxins in human body was measured and the antioxidant activity was measured as good but the activity of SOD (antioxidant enzyme) was significantly lower than that of vitamin C.
2.2 세포 독성2.2 Cytotoxicity
본 발명에서 각 세포의 배양은 10% fetal bovine serum (FBS)과 을 첨가한 Dulbeco's modified eagle's medium (DMEM) 배지를 사용하였으며, 37℃, 5% CO2 incubator에 적응시켜 계대 배양하였다.In the present invention, each cell was cultured in Dulbeco's modified eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37 ° C in a 5% CO2 incubator.
세포 생존율 측정은 Camichael의 방법(비특허문헌 5)에 따라 실시하였다. 세포 생존율을 확인하기 위한 MTT 검색법은 96 well plate를 사용하며 ELISA reader (multiwell microplate reader)를 이용하여 많은 시료를 간단하게 판독할 수 있어 세포독성 및 세포증식 검색법으로서 널리 사용되고 있는 방법 중의 한 방법이다. 각 세포 melanoma (B16F10), fibroblast (CCRF), macrophage (Raw264.7) cell를 96 well plate에 0.6~8x103 cells/well이 되게 0.18 mL 분주하고 시료를 농도 별로 조제하여 0.02 mL 첨가한 후 37℃ , 5% CO2 incubator에서 24시간 배양하였다. 대조군은 시료와 동량의 멸균수를 첨가하여 동일한 조건으로 배양하였다. 여기에 5 mg/mL 농도로 제조한 MTT 용액 0.02 mL를 첨가하여 4시간 배양한 후 배양액을 제거하고 각 well당 DMSO: Ethanol (1: 1) 0.15 mL를 가하여 실온에서 30분간 반응시킨 뒤 ELISA reader로 550 nm에서 흡광도를 측정하였다. 세포 생존율 측정은 시료 용액의 첨가군과 무첨가군의 흡광도 감소율로 나타내었다. MTT assay (B16F10 melanoma) 실험결과 그라비올라 열수추출물은 10ug/ml 농도에서 세포 생존율이 80% 이상으로 확인하였으며, 그라비올라 에탄올추출물은 1ug/ml 농도에서 80% 이상의 세포생존율을 확인하였다(도 5).
Cell viability was measured according to Camichael's method (Non-Patent Document 5). MTT screening for cell viability is performed using a 96-well plate and an ELISA reader (multiwell microplate reader), which can be used to easily read many samples and is one of the widely used methods for cytotoxicity and cell proliferation detection to be. Each cell melanoma (B16F10), fibroblast (CCRF), and macrophage (Raw264.7) cells were seeded in a 96 well plate with 0.18 mL of 0.6 to 8 × 10 3 cells / well. , 5% CO 2 incubator for 24 hours. In the control group, the same amount of sterilized water as the sample was added and the cells were cultured under the same conditions. After adding 0.02 mL of MTT solution (5 mg / mL) for 4 hours, remove the culture medium, add 0.15 mL of DMSO: Ethanol (1: 1) to each well and incubate at room temperature for 30 minutes. Absorbance at 550 nm. The cell viability was measured by the absorbance reduction ratio of the sample solution and the no-added sample solution. MTT assay (B16F10 melanoma) The cell viability was found to be 80% or more at a concentration of 10 ug / ml, and the cell viability of graviola ethanol extract was found to be 80% or more at a concentration of 1 ug / ml (FIG. 5) .
2.3 미백 효과2.3 Whitening effect
1) 버섯 유래의 티로시나아제 저해능 1) Insecticidal activity of tyrosinase derived from mushroom
티로시나아제 저해능 측정은 Yagi 등(비특허문헌 6)의 방법에 따라 측정하였다. 반응구는 0.175 M 인산나트륨 완충액 (pH 6.8) 0.5 mL에 10 mM L-DOPA를 녹인 기질 액 0.2 mL 및 시료용액 0.1 mL의 혼합액에 버섯 티로시나아제 (110 U/mL) 0.2 mL를 첨가하여 37?에서 2분간 반응시켜 반응 액 중에 생성된 DOPA chrome을 475 nm에서 측정하였다. 티로시나아제 저해능은 시료용액의 첨가구와 무 첨가 군의 흡광도 감소율로 나타내었다(도 6).
Tyrosinase inhibitory activity was measured according to the method of Yagi et al. (Non-Patent Document 6). To the reaction mixture, 0.2 mL of mushroom tyrosinase (110 U / mL) was added to a mixture of 0.2 mL of the substrate solution in which 10 mM L-DOPA had been dissolved and 0.1 mL of the sample solution in 0.5 mL of 0.175 M sodium phosphate buffer (pH 6.8) For 2 minutes, and the DOPA chrome produced in the reaction solution was measured at 475 nm. The inhibitory effect of tyrosinase was shown by the rate of decrease of the absorbance of the sample solution with and without the sample solution (Fig. 6).
2) B16F10에서의 멜라닌(melanin) 생합성 저해능2) Inhibition of melanin biosynthesis in B16F10
멜라닌 생합성 저해능 측정은 Hosoi의 방법(비특허문헌 7)에 따라 측정하였다. DMEM 배지로 배양된 melanoma cell을 100 mm culture dish에 2 x 106 cell/dish가 되게 분주하고 24시간 배양 후 시료를 농도별로 조제하여 2 mL 첨가하고, 48시간 후에 PBS (pH 7.4)으로 세척하였다. 그 다음 0.25 M trypsin-EDTA 용액으로 세포를 탈착한 후 수확한 세포를 1 x 106 세포 당 1 mL의 5% TCA로 처리하고, 2,500 rpm으로 2회 원심분리 한 후 분리된 melanin을 PBS으로 세척한 뒤 에테르: 에탄올 (1:3) 1 mL를 가하여 2회 원심 분리한 후 에테르 1 mL로 세척 건조시켰다. 건조된 멜라닌에 1 N NaOH를 1 mL 가하여 80?에서 1시간 반응시킨 후 분광 광도계 405 nm에서 흡광도를 측정하였다. 멜라닌 생합성 저해는 시료용액의 첨가군과 무첨가군의 흡광도 감소율로 나타내었다.
Measurement of melanin biosynthesis inhibitory activity was carried out according to the method of Hosoi (non-patent reference 7). The melanoma cells cultured in DMEM medium were divided into 2 × 10 6 cells / dish in a 100 mm culture dish. After culturing for 24 hours, 2 mL of the sample was prepared and the cells were washed with PBS (pH 7.4) 48 hours later . The cells were then desalted with 0.25 M trypsin-EDTA solution and harvested. The cells were treated with 1 mL of 5% TCA per 1 × 10 6 cells, centrifuged twice at 2,500 rpm, and the isolated melanin was washed with PBS Then, 1 mL of ether: ethanol (1: 3) was added, and the mixture was centrifuged two times, washed with 1 mL of ether and dried. 1 mL of 1 N NaOH was added to the dried melanin, reacted at 80 ° C for 1 hour, and the absorbance was measured at 405 nm using a spectrophotometer. The inhibition of melanin biosynthesis was expressed by the absorbance reduction rate of the addition group of the sample solution and the no addition group.
3) 프로-콜라겐 합성 속도3) Pro-collagen synthesis rate
그라비올라 추출물의 프로콜라겐 합성에 대한 효과를 측정하였다(도 7).
The effect of graviola extract on procollagen synthesis was measured (Fig. 7).
2.4 항균력2.4 Antimicrobial activity
전 배양 및 본 배양을 위한 액체 배지는 Staphylococcus epidermidis (S. epidermidis) 및 Escherichia coli (E.coli)의 액체배지로는 nutrient broth (NB)를 Staphylococcus aureus (S. aureus)의 액 체 배지로는 tryptic soy broth (TSB)를 사용했고, Propionibacterium acnes (P. acnes) 균은 Gifu anaerobic medium (GAM)배지를 사용했다. S. epidermidis 및 E. coli의 고체배지는 nutrient agar (NA)를 사용했으며, S. aureus의 액체배지로는 tryptic soy agar (TSA)를 사용하여 배양했으며, P.acnes균은 Gifu anaerobic medium (GAM) 배지에 agar를 첨가하여 본 실험에 사용하였다. P.acnes 균은 5%, CO2 incubator에서 37℃로 배양하였고, 그 외의 모든 균주는 BOD incubator에서 37℃로 배양하였다.The nutrient broth (NB) was used as a liquid medium for Staphylococcus epidermidis (Escherichia coli) and Escherichia coli (E. coli) as a liquid medium for pre-culture and main cultivation, tryptic Soy broth (TSB) was used, and Propionibacterium acnes (P. acnes) used Gifu anaerobic medium (GAM) medium. S. epidermidis and E. coli were cultured using nutrient agar (NA), S. aureus was cultured using tryptic soy agar (TSA), and P. acnes was cultured in Gifu anaerobic medium (GAM ) Agar was added to the medium and used in this experiment. P. acnes was incubated at 37 ° C in a 5
그라비올라 열수 추출물의 항균력을 테스트하였다. 대조군으로는 일반 정제수를 사용하였다. 황색포도상구균(Staphylococcus aureus), 대장균(E. coli)을 그라비올라 수 및 일반 정제수가 포함된 배지에서 4주간 배양하여 항균력을 확인하였다. 항균력 측정은 paper disc법으로 측정하였다. 평판 배지에 single colony 배양된 각 균주를 1 백금이를 취해서 액체배지 10 mL에서 18~24시간 배양하여 활성화시킨 후, 다시 액체배지 10 mL에 균액을 0.1 mL접종하여 3~6시간 본 배양한 후 평판배지 1개당 균수가 약 1×107 cells이 되게 접종하여 멸균 면봉으로 균일하게 도말하였다. 멸균된 filter paper disc (8 mm, Whatman, Japan)를 고체 평판배지에 올려놓은 다음 50 μL/disc가 되도록 시료를 농도별로 흡수시켜 37℃에서 18~24시간 배양하여 disc 주위의 clear zone (mm)의 직경을 측정하였다(도 8).
The antibacterial activity of the graviola hot water extract was tested. Regular purified water was used as a control. Staphylococcus aureus and E. coli were cultivated in a medium containing graviola water and general purified water for 4 weeks to confirm the antibacterial activity. The antimicrobial activity was measured by paper disc method. Each strain cultivated in a single colony on a plate medium was inoculated in 10 mL of a liquid culture medium for 0.1 to 3 mL for 3 to 6 hours, The cells were inoculated at a density of about 1 x 10 < 7 > cells per plate medium and homogeneously plated with a sterilized cotton swab. The sterilized filter paper discs (8 mm, Whatman, Japan) were placed on a solid plate medium and then absorbed at a concentration of 50 μL / disc and incubated at 37 ° C for 18-24 hours to obtain clear zone (mm) (Fig. 8).
2.5 항균 펩타이드의 발현2.5 Expression of Antimicrobial Peptides
그라비올라 추출물을 인간 피부각질세포(keratinocyte)에 처리한 후, 피부세포 자체에서 발현되는 항균 펩타이드인 CAMP(Cathelicidin antimicrobial peptide) 및 LL-37의 발현을 확인하였다. MITF, TRP-1, TRP-2, MMP-1, iNOS, COX-2 활성을 확인하기 위하여 cell line (B16F10, CCRF, Raw246.7)을 tissue culture dish에 cell seeding 후 24시간 동안 배양하여 cell을 안정화시켰다. 배지를 제거한 후 시료를 농도별로 처리한 배지로 24~48시간 배양한 후 다시 배지를 제거하고 PBS로 2번 세척해주었다. RIPA buffer 10 ml에 complete mini 1 tab를 가하여 100 uL로 용해해서 4℃, 12,000 rpm에서 20분간 원심 분리하였다. 원심 분리하여 얻은 단백질은 bovine serum albumin (BSA)를 표준물질로 하여 Bradford assay로 정량하였으며, 10% SDS-polyacrylamide gel을 이용하여 120 V에서 1시간 전기영동 한다. loading이 끝나면 polyvinylidenedifluoriden (PVDF)을 사용하여 30~40 V에서 2시간 이상 transfer 하였다. transfer가 끝나면 ponceau S에 담근 후 band를 확인하고 TBST로 2회 이상 세척한 후 5% skin milk로 overnight 시켜 background는 제거시켰다. 3회 washing 후에 1차 antibody (1: 1000)를 1시간 동안 붙인 후 2차 antibody (1: 1000)를 붙이고 ECL kit (Amersham Pharmacia, England)를 이용하여 film에 옮겨 측정하였다. Band density는 Gel doc (Bio-rad, America)으로 확인하였다(도 9).
After treatment of graviola extract with human keratinocyte, the expression of antimicrobial peptides CAMP (Cathelicidin antimicrobial peptide) and LL-37 expressed in skin cells themselves was confirmed. Cell line (B16F10, CCRF, Raw246.7) was cultured in tissue culture dish for 24 hours to confirm MITF, TRP-1, TRP-2, MMP-1, iNOS and COX- Stabilized. After the medium was removed, the sample was incubated in a concentration-treated medium for 24 to 48 hours. Then, the medium was removed again and washed twice with PBS. To 10 ml of RIPA buffer, complete mini 1 tab was added and dissolved in 100 μl, and centrifuged at 4 ° C and 12,000 rpm for 20 minutes. The proteins obtained by centrifugation were quantified by Bradford assay using bovine serum albumin (BSA) as a standard and electrophoresis at 120 V for 1 hour using 10% SDS-polyacrylamide gel. After loading, polyvinylidenedifluoriden (PVDF) was used and transferred at 30 ~ 40 V for more than 2 hours. At the end of the transfer, the pancreas was immersed in ponceau S and the band was confirmed. After washing twice with TBST, the skin was overlaid with 5% skin milk to remove the background. After washing three times, the primary antibody (1: 1000) was stuck for 1 hour, and then the secondary antibody (1: 1000) was added and transferred to a film using an ECL kit (Amersham Pharmacia, England). The band density was confirmed by Gel doc (Bio-rad, America) (Fig. 9).
2.6 주름개선 효과 2.6 Wrinkle-reducing effect
엘라스타아제(Elastase) 저해능 측정에 의해 그라비올라 추출물의 주름개선 효과를 측정하였다. Elastase 저해능 측정은 Cannell 등(비특허문헌 7)의 방법에 따라 측정하였다. 기질로서 N-succinyl-(L-Ala)3-p-nitroanilide를 사용하여 37?에서 20분간 기질로부터 생성되는 p-nitroanilide의 생성량을 405 nm에서 측정하였다. 즉, 각 시험용액을 일정 농도가 되도록 조제하여 0.5 mL씩 시험관에 취하고, 50 mM tris-HCl buffer (pH 8.6)에 녹인 porcine pancreas elastase (2.5 U/mL)용액 0.5 mL을 가한 후 기질로 50 mM tris-HCl buffer (pH 8.6)에 녹인 N-succinyl-(L-Ala)3-p-nitroanilide (0.5 mg/mL)을 첨가하여 20분간 반응시켜 측정하였다. elastase 저해능은 시료용액의 첨가구와 무 첨가 군의 흡광도 감소율로 나타내었다(도 10).
The wrinkle-reducing effect of the graviola extract was measured by measuring the elastase inhibitory activity. Elastase inhibition assay was performed according to Cannell et al. (Non-patent reference 7). The amount of p-nitroanilide produced from the substrate for 20 min at 37 ° C was measured at 405 nm using N-succinyl- (L-Ala) 3-p-nitroanilide as a substrate. 0.5 mL of porcine pancreas elastase (2.5 U / mL) dissolved in 50 mM tris-HCl buffer (pH 8.6) was added to each test solution, and 50 mM N-succinyl- (L-Ala) 3-p-nitroanilide (0.5 mg / mL) dissolved in tris-HCl buffer (pH 8.6) was added and reacted for 20 minutes. The elastase inhibitory activity was expressed by the absorbance decreasing rate of the sample solution added group and the no-added group (FIG. 10).
2.7 항염증 효과2.7 Anti inflammatory effect
Nitric oxide (NO) 측정은 cell의 supernatant에서의 NO의 량을 nitrite and nitrate로서 측정을 하였다(비특허문헌 8). Nitrite에 대한 nitrate로 환원된 후의 안전한 형태인 griess reagent (Sigma, USA)를 사용하였으며, 6 well plate에 2×106개의 cell을 confluence가 80%일 때, PBS로 2번 washing한 후 무혈청 배지를 사용하여 12시간 이상 배양시킨 다음 lipopolysacchride (LPS) 10 μg/mL을 control 군을 뺀 모든 well에 다 넣어서 자극시켰다. 2시간 후에 시료를 농도별로 처리하여 실험하였다. NO 생성량은 24시간 후에 상층액을 모아 griess regent로 10분간 반응시킨 후에 540 nm에서 흡광도로 측정하였다(도 11). 또한, 그라비올라 추출물의 iNOS 발현 억제효과를 측정하였다(도 12).
Nitric oxide (NO) measurement was carried out by measuring the amount of NO in the supernatant of the cell as nitrite and nitrate (Non-Patent Document 8). Griess reagent (Sigma, USA), a safe form after nitrite reduction to nitrite, was used. In a 6-well plate, 2 × 106 cells were washed twice with PBS at 80% confluence, (LPS) (10 μg / mL) was added to all wells except the control group for stimulation. After 2 hours, the samples were treated by concentration. The amount of NO produced after 24 hours was measured by absorbance at 540 nm after collecting the supernatant and reacting for 10 minutes with griess regent (FIG. 11). In addition, the inhibitory effect of graviola extract on iNOS expression was measured (Fig. 12).
모발 Hair 화장료Cosmetics 조성물의 제조 Preparation of composition
본 발명에 따른 모발 화장료 조성물 100 중량부를 기준으로, 1) 카보머 0.2 중량부 및 디소듐이디티에이 0.07 중량부를 정제수 15 중량부에 넣고 90℃까지 가온하여 용해시켰다. 용해물에 대하여 여과를 실시하였다; 2) 시트릭애씨드 0.2 중량부, 솔잣나무열매추출물 0.2 중량부, 글리세린 1.7 중량부, 디메치콘 2 중량부, 소듐라우릴설페이트 10 중량부 및 코카마이도프로필베타인 7 중량부를 혼합하여 70℃까지 가온하여 용해시킨 후 상기 1) 단계의 여과물과 혼합 교반하였다; 3) 코카마이드디에이 7 중량부, 아이오도프로피닐부틸카바메이트 0.04 중량부 및 글라이콜디스테아레이트 0.4 중량부를 70℃까지 가온하여 용해시키고 여과하여 상기 단계 2)의 생성물과 혼합 교반한 후, 60℃까지 냉각하였다; 4) 세트리모늄클로라이드 2 중량부, 향료 0.5 중량부, 트리에탄올아민 0.5 중량부, 소듐클로라이드 0.5 중량부, 하이드롤라이즈드케라틴 1 중량부, 하수오추출물 0.143 중량부, 홍삼추출물 0.143 중량부, 백지추출물 0.143 중량부, 한련초추출물 0.143 중량부, 당귀추출물 0.143 중량부, 석류추출물 0.143 중량부, 대황추출물 0.143 중량부, 카퍼트리펩타이드 0.2 중량부, 그라비올라추출물 0.5 중량부, 소듐라우레스에테르설페이트 25 중량부 및 정제수 대체(그라비올라 수) 25 중량부를 상기 단계 3)의 60℃로 냉각된 혼합물과 혼합교반하여 35℃까지 냉각한 후 여과시켜 모발 화장료 조성물을 제조하였다.
1) Carbomer (0.2 part by weight) and disodium iodide (0.07 part by weight) were added to 15 parts by weight of purified water and heated to 90 占 폚 to dissolve the hair cosmetic composition according to 100 parts by weight of the hair cosmetic composition according to the present invention. The liquor was filtered; 2) 0.2 part by weight of citric acid, 0.2 part by weight of sour pine nut extract, 1.7 parts by weight of glycerin, 2 parts by weight of dimethicone, 10 parts by weight of sodium lauryl sulfate and 7 parts by weight of cocamidopropyl betaine were mixed, Warmed to dissolve and mixed with the filtrate of step 1); 3) 7 parts by weight of cocamide diad, 0.04 parts by weight of iodopropynyl butylcarbamate and 0.4 parts by weight of glycol distearate were dissolved by heating to 70 ° C, filtered and mixed with the product of step 2) Gt; 60 C < / RTI > 4) Tweezers of settimonium chloride, 0.5 parts by weight of fragrance, 0.5 parts by weight of triethanolamine, 0.5 parts by weight of sodium chloride, 1 part by weight of hydrolyzed keratin, 0.143 parts by weight of Sasao extract, 0.143 parts by weight of red ginseng extract, 0.143 part by weight of the myrtle extract, 0.143 part by weight of the myrtle extract, 0.143 part by weight of the prawn extract, 0.143 part by weight of the prawn extract, 0.143 part by weight of the rhododendron extract, 0.2 part by weight of the caplet tripeptide, 0.5 part by weight of graviola extract, And 25 parts by weight of purified water substitute (graviola water) were mixed and stirred with the mixture cooled to 60 ° C in step 3), cooled to 35 ° C, and filtered to prepare a hair cosmetic composition.
Claims (4)
1) 정제수, 카보머 및 디소듐이디티에이를 90℃까지 가온하여 용해한 후 여과하는 단계;
2) 시크릭애씨드, 솔잣나무열매추출물, 글리세린, 디메치콘, 소듐라우릴설페이트 및 코카마이도프로필베타인을 70℃까지 가온하여 용해한 후 상기 1) 단계의 여과물과 혼합교반하는 단계;
3) 코카마이드디이에이, 아이오도프로피닐부틸카바메이트 및 글라이콜디스테아레이트를 70℃까지 가온하여 용해한 후 여과하여 상기 2) 단계의 생성물과 혼합교반하여 60℃까지 냉각하는 단계;
4) 세트리모늄클로라이드, 향료, 트리에탄올아민, 소듐클로라이드, 하이드롤라이즈케라틴, 하수오추출물, 홍삼추출물, 백지추출물, 한련초추출물, 당귀추출물, 석류추출물, 대황추출물, 카퍼트리펩타이드, 그라비올라 에탄올 추출물, 소듐라우레스에테르설페이트 및 그라비올라 열수 추출물을 상기 3) 단계의 생성물과 혼합 교반하여 60℃까지 냉각하고 여과하는 단계.
A method for producing a cosmetic composition for hair loss prevention and scalp comprising the steps of:
1) dissolving in purified water, carbomer and disodium edithio by heating to 90 ° C and then filtering;
2) dissolving Saccharic acid, Solanum tuberosum extract, glycerin, dimethicone, sodium lauryl sulfate and cocamidopropyl betaine to 70 ° C and mixing and mixing with the filtrate of step 1);
3) dissolving cocamide diame, iodopropionyl butylcarbamate and glycol distearate by heating to 70 ° C, filtering and mixing the product with the product of step 2), and cooling to 60 ° C;
4) Rumonium chloride, fragrance, triethanolamine, sodium chloride, hydrolyzed keratin, dewatering extract, red ginseng extract, white ginseng extract, hanchikcho extract, angelica extract, pomegranate extract, rhubarb extract, Sodium laureth ether sulfate and graviola hot water extract are mixed with the product of step 3), cooled to 60 ° C, and filtered.
정제수 13 내지 17 중량부, 카보너 0.1 내지 0.3 중량부, 디소듐이디티에이 0.05 내지 0.1 중량부, 시크릭애씨드 0.1 내지 0.3 중량부, 솔잣나무열매추출물 0.1 내지 0.3 중량부, 글리세린 1.5 내지 2.0 중량부, 디메치콘 1.5 내지 2.5 중량부, 소듐라우릴설페이트 8 내지 12 중량부, 코카마이도프로필베타인 6 내지 8 중량부, 코카마이드디이에이 6 내지 8 중량부, 아이오도프로피닐부틸카바메이트 0.03 내지 0.05 중량부, 글라이콜디스테아레이트 0.3 내지 0.5 중량부, 세트리모늄클로라이드 1.8 내지 2.2 중량부, 향료 0.3 내지 0.7 중량부, 트리에탄올아민 0.3 내지 0.7 중량부, 소듐클로라이드 0.3 내지 0.7 중량부, 하이드롤라이즈드케라틴 0.8 내지 1.2 중량부, 하수오추출물 0.13 내지 0.15 중량부, 홍삼추출물 0.13 내지 0.15 중량부, 백지추출물 0.13 내지 0.15 중량부, 한련초추출물 0.13 내지 0.15 중량부, 당귀추출물 0.13 내지 0.15 중량부, 석류추출물 0.13 내지 0.15 중량부, 대황추출물 0.13 내지 0.15 중량부, 카퍼트리펩타이드 0.15 내지 0.25 중량부, 그라비올라 에탄올 추출물 0.4 내지 0.6 중량부, 소듐라우에스에테르설페이트 23 내지 27 중량부 및 그라비올라 열수추출물 23 내지 27중량부로 혼합하는 것을 특징으로 하는 방법.
The method according to claim 1,
0.1 to 0.3 parts by weight of purified water, 0.1 to 0.3 parts by weight of carborane, 0.05 to 0.1 part by weight of disodium dithiae, 0.1 to 0.3 part by weight of cicric acid, 0.1 to 0.3 part by weight of sour pine fruit extract, 1.5 to 2.5 parts by weight of dimethicone, 8 to 12 parts by weight of sodium lauryl sulfate, 6 to 8 parts by weight of cocamidopropyl betaine, 6 to 8 parts by weight of cocamide diisocyanate, 0.03 of iodopropynyl butyl carbamate 0.3 to 0.7 parts by weight of triethanolamine, 0.3 to 0.7 part by weight of sodium chloride, 0.3 to 0.7 parts by weight of sodium chloride, 0.3 to 0.5 parts by weight of glycerol distearate, 1.8 to 2.2 parts by weight of settimorium chloride, 0.3 to 0.7 parts by weight of fragrance, 0.13 to 0.15 parts by weight of a red ginseng extract, 0.13 to 0.15 parts by weight of a white ginseng extract, 0.13 to 0.15 parts by weight of a ginseng extract, 0.13 to 0.15 parts by weight of a red ginseng extract, 0.13 to 0.15 part by weight of the Angelica giganta extract, 0.13 to 0.15 part by weight of the Angelica giganta extract, 0.13 to 0.15 part by weight of the pomegranate extract, 0.13 to 0.15 part by weight of the rhubarb extract, 0.15 to 0.25 part by weight of the kappa tripeptide, 0.4 to 0.6 part by weight of the graviola ethanol extract, 23 to 27 parts by weight of ether sulfate and 23 to 27 parts by weight of graviola hot water extract.
정제수 15 중량부, 카보너 0.2 중량부, 디소듐이디티에이 0.07 중량부, 시크릭애씨드 0.2 중량부, 솔잣나무열매추출물 0.2 중량부, 글리세린 1.7 중량부, 디메치콘 2 중량부, 소듐라우릴설페이트 10 중량부, 코카마이도프로필베타인 7 중량부, 코카마이드디이에이 7 중량부, 아이오도프로피닐부틸카바메이트 0.04 중량부, 글라이콜디스테아레이트 0.4 중량부, 세트리모늄클로라이드 2 중량부, 향료 0.5 중량부, 트리에탄올아민 0.5 중량부, 소듐클로라이드 0.5 중량부, 하이드롤라이즈드케라틴 1 중량부, 하수오추출물 0.143 중량부, 홍삼추출물 0.143 중량부, 백지추출물 0.143 중량부, 한련초추출물 0.143 중량부, 당귀추출물 0.143 중량부, 석류추출물 0.143 중량부, 대황추출물 0.143 중량부, 카퍼트리펩타이드 0.2 중량부, 그라비올라 에탄올추출물 0.5 중량부, 소듐라우에스에테르설페이트 25 중량부 및 그라비올라 열수추출물 25 중량부로 혼합하는 것을 특징으로 하는 방법.
The method according to claim 1,
15 parts by weight of purified water, 0.2 part by weight of carbonara, 0.07 part by weight of disodium diteary, 0.2 part by weight of cyclic acid, 0.2 part by weight of sour pine nut extract, 1.7 parts by weight of glycerin, 2 parts by weight of dimethicone, 10 parts by weight, cocamidopropyl betaine 7 parts by weight, cocamide dieye 7 parts by weight, iodopropynyl butyl carbamate 0.04 part by weight, glycol distearate 0.4 part by weight, settimorium chloride 2 parts by weight 0.5 part by weight of fragrance, 0.5 part by weight of triethanolamine, 0.5 part by weight of sodium chloride, 1 part by weight of hydrolyzed keratin, 0.143 part by weight of sulfoisophthalate extract, 0.143 part by weight of red ginseng extract, 0.143 part by weight of blanched extract, 0.143 weight part of Angelica giganta extract, 0.143 weight part of pomegranate extract, 0.143 weight part of rhubarb extract, 0.2 weight part of capper tripeptide, 0.5 weight part of graviola ethanol extract, 25 parts by weight of leucose and 25 parts by weight of graviola hot water extract.
A hair cosmetic composition for hair loss prevention and scalp, which is produced by the method according to any one of claims 1 to 3.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140078896A KR20160001102A (en) | 2014-06-26 | 2014-06-26 | Hair cosmetic composition comprising the oriental medicin extract of Graviola for improving state of scalp and preventing hair loss |
| KR1020220002831A KR102436816B1 (en) | 2014-06-26 | 2022-01-07 | Cosmetic composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140078896A KR20160001102A (en) | 2014-06-26 | 2014-06-26 | Hair cosmetic composition comprising the oriental medicin extract of Graviola for improving state of scalp and preventing hair loss |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220002831A Division KR102436816B1 (en) | 2014-06-26 | 2022-01-07 | Cosmetic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160001102A true KR20160001102A (en) | 2016-01-06 |
Family
ID=55165033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140078896A Ceased KR20160001102A (en) | 2014-06-26 | 2014-06-26 | Hair cosmetic composition comprising the oriental medicin extract of Graviola for improving state of scalp and preventing hair loss |
| KR1020220002831A Active KR102436816B1 (en) | 2014-06-26 | 2022-01-07 | Cosmetic composition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220002831A Active KR102436816B1 (en) | 2014-06-26 | 2022-01-07 | Cosmetic composition |
Country Status (1)
| Country | Link |
|---|---|
| KR (2) | KR20160001102A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106423882A (en) * | 2016-11-09 | 2017-02-22 | 陕西科技大学 | Chinese-dates automatic grading equipment |
| CN108992385A (en) * | 2018-08-27 | 2018-12-14 | 天津市康婷生物工程有限公司 | Hair essence is educated in a kind of hair follicle reparation |
| KR102080412B1 (en) * | 2018-11-22 | 2020-02-21 | 이정민 | Shampoo comprising the extract of graviola for improving condition of scalp and preventing hair loss |
| KR20200042783A (en) * | 2018-10-16 | 2020-04-24 | 홍연희 | Manufacturing method of hair loss prevention shampoo containing graviola component extracted in two steps |
| KR102229499B1 (en) * | 2020-10-21 | 2021-03-18 | 세아준뷰티 주식회사 | Composition for hair care including copper-peptide complex |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240169158A (en) * | 2023-05-23 | 2024-12-03 | 이호규 | High functional cosmetic composition using extract of Alpinia officinarum and manufacturing method thereof |
| KR102676679B1 (en) * | 2023-07-20 | 2024-06-25 | 주식회사 바이오에프디엔씨 | Composition comprising Graviola callus lysate extract as an active ingredient having skin whitening, antioxidant, skin condition improvement and hair loss inhibitory effects |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100780180B1 (en) | 2006-12-01 | 2007-11-28 | (주)바이오에프디엔씨 | Herbal composition for preventing hair loss and promoting hair growth, and method of manufacturing the same |
| KR101103651B1 (en) | 2011-02-01 | 2012-01-11 | 주식회사 예지미인 | Hair cosmetic composition containing herbal extracts having hair loss prevention and hair growth promoting effect |
| KR101155502B1 (en) | 2008-07-09 | 2012-06-15 | (주) 피엘코스메틱 | Oriental hair restorer and the method using the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0912433A (en) * | 1995-04-28 | 1997-01-14 | Shiseido Co Ltd | Composition for head |
| KR101212707B1 (en) * | 2010-05-26 | 2012-12-14 | 재단법인 고창복분자연구소 | Cosmetics and toiletries containing extract of Rubus coreanum seeds |
| ITVA20110008A1 (en) * | 2011-03-25 | 2012-09-26 | Lamberti Spa | DETERGENT COMPOSITIONS |
| KR101243530B1 (en) * | 2011-06-29 | 2013-03-20 | 김광우 | Hair Cosmetic Composition for Growth Promotion of Hairs Containing Extracted Concentrated Solution From Pine Leaves |
-
2014
- 2014-06-26 KR KR1020140078896A patent/KR20160001102A/en not_active Ceased
-
2022
- 2022-01-07 KR KR1020220002831A patent/KR102436816B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100780180B1 (en) | 2006-12-01 | 2007-11-28 | (주)바이오에프디엔씨 | Herbal composition for preventing hair loss and promoting hair growth, and method of manufacturing the same |
| KR101155502B1 (en) | 2008-07-09 | 2012-06-15 | (주) 피엘코스메틱 | Oriental hair restorer and the method using the same |
| KR101103651B1 (en) | 2011-02-01 | 2012-01-11 | 주식회사 예지미인 | Hair cosmetic composition containing herbal extracts having hair loss prevention and hair growth promoting effect |
Non-Patent Citations (7)
| Title |
|---|
| Blois MS. 1958, Nature, 26, 1199-1120. |
| Carmichael J 외, 1987, Cancer Res., 47(4), 936-942. |
| Hosoi J 외, 1985, Cancer Res., 45(4), 1474-1478. |
| Marklund S 외, 1974, Eur J Biochem., 47(3), 469-474. |
| Roberta R 외, 1999, Free radical biology & Medicine, 26(9/10), 1231-1237. |
| Stirpe F 외, 1969, J. Biol. Chem., 244(14), 3855-3863. |
| Yagi A 외, 1986, 3981, 517-519. |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106423882A (en) * | 2016-11-09 | 2017-02-22 | 陕西科技大学 | Chinese-dates automatic grading equipment |
| CN108992385A (en) * | 2018-08-27 | 2018-12-14 | 天津市康婷生物工程有限公司 | Hair essence is educated in a kind of hair follicle reparation |
| KR20200042783A (en) * | 2018-10-16 | 2020-04-24 | 홍연희 | Manufacturing method of hair loss prevention shampoo containing graviola component extracted in two steps |
| KR102080412B1 (en) * | 2018-11-22 | 2020-02-21 | 이정민 | Shampoo comprising the extract of graviola for improving condition of scalp and preventing hair loss |
| KR102229499B1 (en) * | 2020-10-21 | 2021-03-18 | 세아준뷰티 주식회사 | Composition for hair care including copper-peptide complex |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220027092A (en) | 2022-03-07 |
| KR102436816B1 (en) | 2022-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102436816B1 (en) | Cosmetic composition | |
| Tadić et al. | Lady’s mantle (Alchemilla vulgaris L., Rosaceae): A review of traditional uses, phytochemical profile, and biological properties | |
| ES2959130T3 (en) | Moringa peregrina seed cake extract, its obtaining procedure and its use in cosmetic or nutricosmetic compositions | |
| KR20140105976A (en) | Cosmetic composition comprising lactobacillus fermented solution having anti-oxidation, whitening and anti-wrinkle effect | |
| KR101494661B1 (en) | Composition for hair or scalp treatment comprising fermented black garlic residue and method of preparing the same | |
| KR101263547B1 (en) | Cosmetic composition comprising green tea seed coater extract having anti-oxidative or anti-inflammatory activity | |
| KR20170133721A (en) | A composition comprising extract of inula japonica thunberg, epimedium koreanum and knotgrass as active ingrediant for functional cosmetics | |
| KR20210091430A (en) | Cosmetic composition containing natural complex extracts as active ingredient | |
| KR101677460B1 (en) | Cosmetic composition comprising allergen removed water soluble royal jelly for skin whitening and anti-aging activity | |
| KR101243219B1 (en) | Skin whitening and anti-wrinkle composition comprising a fermented plant extract in Ulleung island | |
| KR20160074116A (en) | Cosmetic composition containing Crataegis fructus fermented extract | |
| KR102063686B1 (en) | Skin external composition containing extract of soybean root | |
| KR20200018879A (en) | Natural cosmetic formulation with excellent effect for skin-microbiome homeostasis and anti-inflammation | |
| KR102612017B1 (en) | Composition for skin improvement comprising multiple extract | |
| KR20100121352A (en) | A composition comprising complex crude drug extract for anti-aging and improvement of skin | |
| KR101293007B1 (en) | Anti-oxidant and anti-wrinkle composition comprising a fermented juice of jujube fruit | |
| KR101793104B1 (en) | Cosmetic composition for whitening skin comprising mixed extract of Cudrania tricuspidata leaf and Morus alba leaf as effective component | |
| KR101243220B1 (en) | Skin whitening and anti-wrinkle composition comprising a fermented plant extract in Ulleung island | |
| KR101746158B1 (en) | Composition for ameliorating atopic dermatitis comprising Gypsophila oldhamiana extract and use thereof | |
| KR102437871B1 (en) | Composition for preventing or improving of skin wrinkle or skin aging comprising roasted dried-radish-slices extracts, and healthy food comprising the composition | |
| KR20130052288A (en) | Cosmetic composition comprising the hot spring water extract of nelumbo nucifera gaertner as active ingredient | |
| KR102152407B1 (en) | Cosmetic composition containing phycocyanobilin and its derivative derived from spirulina | |
| KR102171200B1 (en) | Composition for the treatment or improvement of Acne dermatitis comprising 5-aminolevulinic acid hydrochloride and its derivatives | |
| KR20170051077A (en) | Composition comprising extract from liriope platyphylla and natural extract | |
| KR20160146372A (en) | Cosmetic composition with the extract of Rehmannia glutinosa, Scutellaria baicalensis and Isatis indigotica against skin aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20140626 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190626 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20140626 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210524 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20211108 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20210524 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20220107 Patent event code: PA01071R01D |